PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Professor Thomas Powles, MBBS, MRCP, MD - Carrying Through in Advanced/Metastatic Urothelial Carcinoma: Expert Perspectives on Recent Practice‐Changing Data and the Practicalities of Individualizing and Continuing Care With Novel Immunotherapy Maintena
Go online to PeerView.com/RVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Improving outcomes for patients with advanced urothelial carcinoma (UC) has been challenging, with many patients experiencing only short periods of progression-free survival after treatment with first-line chemotherapy. A game changer in many cancers, immunotherapy has provided new avenues for the cancer care team to help their patients with advanced UC live longer. In particular, new data on the use of immunotherapy in the first-line maintenance setting has shown that using immunotherapy before patients’ progress to the second-line setting increases survival without a negative impact on quality of life. In this activity, a panel of experts discusses strategies for incorporating these important data into individualized patient care. Upon completion of this CE activity, participants will be able to: Cite the available clinical evidence on the use of immune checkpoint inhibitors as first-line (1L) maintenance vs. delayed (2L) therapy in patients with advanced UC after response to 1L platinum chemotherapy, Select patients with advanced UC who may be eligible for 1L maintenance therapy with an immune checkpoint inhibitor based on response to initial chemotherapy, PD-L1 status, and other patient- and disease-related factors, Incorporate new clinical evidence and updated guideline recommendations on 1L immunotherapy maintenance regimens into current treatment algorithms for patients with advanced UC.